Date: 2016-05-10
Type of information: Nomination
Compound:
Company: PEP Therapy (France)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On May 10, 2016, Pep Therapy announced that Sophie Lebel-Binay has been appointed as Vice-President research and early clinical development. She will be responsible for the development of PEP-Therapy’s drug candidates and their biomarkers up to clinical trials. She will also take over the management of R&D projects and contribute to the global company scientific strategy. In her previous positions, Sophie was Responsible for nonclinical R&D activities at InnaVirVax, developing innovative immune-based treatments for infectious and major chronic diseases. She was Head of translational programs in oncology at Gustave Roussy Cancer Center, where she coordinated several research programs and implemented innovative technology platforms dedicated to translational research. Prior to this, she was the R&D Director of the pharmaco-toxicology department at Onxeo, responsible for the preclinical development of biotherapies and new chemical entities. During her carrier, Sophie held various positions, at INSERM, CEA, Centre d’Immunologie Pierre Fabre, VIRalliance and Stallergenes.
Financial terms:
Latest news:
